Stephanie J W Shoop-Worrall1,2, Kimme L Hyrich2,3, Lucy R Wedderburn4,5,6, Wendy Thomson7,3, Nophar Geifman1. 1. Centre for Health Informatics, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK. 2. Centre for Epidemiology Versus Arthritis, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK. 3. National Institute for Health Research Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 4. Centre for Adolescent Rheumatology Versus Arthritis at UCL, University College London Hospitals and Great Ormond Street Hospital, London, UK. 5. Infection Inflammation and Rheumatology, UCL Great Ormond Street Institute of Child Health, London, UK. 6. NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK. 7. Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
Abstract
BACKGROUND: Juvenile idiopathic arthritis (JIA) is a heterogeneous disease, the signs and symptoms of which can be summarised with use of composite disease activity measures, including the clinical Juvenile Arthritis Disease Activity Score (cJADAS). However, clusters of children and young people might experience different global patterns in their signs and symptoms of disease, which might run in parallel or diverge over time. We aimed to identify such clusters in the 3 years after a diagnosis of JIA. The identification of these clusters would allow for a greater understanding of disease progression in JIA, including how physician-reported and patient-reported outcomes relate to each other over the JIA disease course. METHODS: In this multicentre prospective longitudinal study, we included children and young people recruited before Jan 1, 2015, to the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort. Participants without a cJADAS score were excluded. To assess groups of children and young people with similar disease patterns in active joint count, physician's global assessment, and patient or parental global evaluation, we used latent profile analysis at initial presentation to paediatric rheumatology and multivariate group-based trajectory models for the following 3 years. Optimal models were selected on the basis of a combination of model fit, clinical plausibility, and model parsimony. FINDING: Between Jan 1, 2001, and Dec 31, 2014, 1423 children and young people with JIA were recruited to CAPS, 239 of whom were excluded, resulting in a final study population of 1184 children and young people. We identified five clusters at baseline and six trajectory groups using longitudinal follow-up data. Disease course was not well predicted from clusters at baseline; however, in both cross-sectional and longitudinal analyses, substantial proportions of children and young people had high patient or parent global scores despite low or improving joint counts and physician global scores. Participants in these groups were older, and a higher proportion of them had enthesitis-related JIA and lower socioeconomic status, compared with those in other groups. INTERPRETATION: Almost one in four children and young people with JIA in our study reported persistent, high patient or parent global scores despite having low or improving active joint counts and physician's global scores. Distinct patient subgroups defined by disease manifestation or trajectories of progression could help to better personalise health-care services and treatment plans for individuals with JIA. FUNDING: Medical Research Council, Versus Arthritis, Great Ormond Street Hospital Children's Charity, Olivia's Vision, and National Institute for Health Research.
BACKGROUND: Juvenile idiopathic arthritis (JIA) is a heterogeneous disease, the signs and symptoms of which can be summarised with use of composite disease activity measures, including the clinical Juvenile Arthritis Disease Activity Score (cJADAS). However, clusters of children and young people might experience different global patterns in their signs and symptoms of disease, which might run in parallel or diverge over time. We aimed to identify such clusters in the 3 years after a diagnosis of JIA. The identification of these clusters would allow for a greater understanding of disease progression in JIA, including how physician-reported and patient-reported outcomes relate to each other over the JIA disease course. METHODS: In this multicentre prospective longitudinal study, we included children and young people recruited before Jan 1, 2015, to the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort. Participants without a cJADAS score were excluded. To assess groups of children and young people with similar disease patterns in active joint count, physician's global assessment, and patient or parental global evaluation, we used latent profile analysis at initial presentation to paediatric rheumatology and multivariate group-based trajectory models for the following 3 years. Optimal models were selected on the basis of a combination of model fit, clinical plausibility, and model parsimony. FINDING: Between Jan 1, 2001, and Dec 31, 2014, 1423 children and young people with JIA were recruited to CAPS, 239 of whom were excluded, resulting in a final study population of 1184 children and young people. We identified five clusters at baseline and six trajectory groups using longitudinal follow-up data. Disease course was not well predicted from clusters at baseline; however, in both cross-sectional and longitudinal analyses, substantial proportions of children and young people had high patient or parent global scores despite low or improving joint counts and physician global scores. Participants in these groups were older, and a higher proportion of them had enthesitis-related JIA and lower socioeconomic status, compared with those in other groups. INTERPRETATION: Almost one in four children and young people with JIA in our study reported persistent, high patient or parent global scores despite having low or improving active joint counts and physician's global scores. Distinct patient subgroups defined by disease manifestation or trajectories of progression could help to better personalise health-care services and treatment plans for individuals with JIA. FUNDING: Medical Research Council, Versus Arthritis, Great Ormond Street Hospital Children's Charity, Olivia's Vision, and National Institute for Health Research.
Authors: Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo Journal: J Rheumatol Date: 2004-02 Impact factor: 4.666
Authors: E J Brewer; J Bass; J Baum; J T Cassidy; C Fink; J Jacobs; V Hanson; J E Levinson; J Schaller; J S Stillman Journal: Arthritis Rheum Date: 1977-03
Authors: Jaime Guzman; Andrew Henrey; Thomas Loughin; Roberta A Berard; Natalie J Shiff; Roman Jurencak; Susanne M Benseler; Lori B Tucker Journal: J Rheumatol Date: 2016-12-15 Impact factor: 4.666
Authors: Roberta A Berard; George Tomlinson; Xiuying Li; Kiem Oen; Alan M Rosenberg; Brian M Feldman; Rae S M Yeung; Claire Bombardier Journal: J Rheumatol Date: 2014-10-01 Impact factor: 4.666
Authors: L Berntson; A Fasth; B Andersson-Gäre; J Kristinsson; P Lahdenne; G Marhaug; S Nielsen; P Pelkonen; E Svensson Journal: J Rheumatol Date: 2001-12 Impact factor: 4.666
Authors: Stephanie J W Shoop-Worrall; Suzanne M M Verstappen; Janet E McDonagh; Eileen Baildam; Alice Chieng; Joyce Davidson; Helen Foster; Yiannis Ioannou; Flora McErlane; Lucy R Wedderburn; W Thomson; Kimme L Hyrich Journal: Arthritis Rheumatol Date: 2018-07-22 Impact factor: 10.995
Authors: Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto Journal: Nat Rev Dis Primers Date: 2022-01-27 Impact factor: 65.038
Authors: Luiza R Grazziotin; Gillian Currie; Marinka Twilt; Maarten J IJzerman; Michelle M A Kip; Hendrik Koffijberg; Gouke Bonsel; Susanne M Benseler; Joost F Swart; Sebastiaan J Vastert; Nico M Wulffraat; Rae S M Yeung; Wineke Armbrust; J Merlijn van den Berg; Deborah A Marshall Journal: Pediatr Rheumatol Online J Date: 2022-07-23 Impact factor: 3.413
Authors: Annie Yarwood; Stephanie Shoop-Worrall; Elena López-Isac; Samantha Louise Smith; Andrew P Morris; John David Bowes; Melissa Tordoff; Kimme L Hyrich; Wendy Thomson; Stephen Eyre Journal: Rheumatology (Oxford) Date: 2022-10-06 Impact factor: 7.046